Description of Research Expertise:
My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A: Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial Lancet 36 (17): 32299-7,2017.
Herati RS, Muselman A, Vella L, Bengsch B, Parkhouse K, Del Alcazar D, Kotzin J, Doyle SA, Tebas P, Hensley SE, Su LF, Schmader KE: Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells Sci Immunol 2 (8): 2017.
Koenig HC, Mounzer K, Daughtridge GW, Sloan CE, Lalley-Chareczko L, Moorthy GS, Conyngham SC, Zuppa AF, Montaner LJ: Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis HIV Med 18 (6): 412-418,2017.
Beigel, J. H., Tebas, P., Elie-Turenne, M. C., Bajwa, E., Bell, T. E., Cairns, C. B., Shoham, S., Deville, J. G., Feucht, E., Feinberg, J., Luke, T., Raviprakash, K., Danko, J., O'Neil, D., Metcalf, J. A., King, K., Burgess, T. H., Aga, E., Lane, H. C., Hughes, M. D., Davey, R. T.: Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study Lancet Respir Med 5 (6): 500-511,2017.
Drechsler, H., Ayers, C., Cutrell, J., Maalouf, N., Tebas, P., Bedimo: Current use of statins reduces risk of HIV rebound on suppressive HAART PLoS One 12 (3): e0172175,2017.
Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M: A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults J Acquir Immune Defic Syndr 74 (2): 193-200,2017.
O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger J S, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F: A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy Open Forum Infect Dis 4 (1): ofw278,2017.
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., Learn, G. H., Proschan, M. A., Kreider, E. F., Blazkova, J., Bardsley, M., Refsland, E. W., Messer, M., Clarridge, K. E., Tustin, N. B., Madden, P. J., Oden, K., O'Dell, S. J., Jarocki, B., Shiakolas, A. R., Tressler, R. L., Doria-Rose, N. A., Bailer, R. T., Ledgerwood, J. E., Capparelli, E. V., Lynch, R. M., Graham, B. S.: Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption N Engl J Med 375 (21): 2037-2050,2016.
Post Frank A, Tebas Pablo, Clarke Amanda, Cotte Laurent, Short William, Abram Michael E, Jiang Shuping, Cheng Andrew, Das Moupali: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. Journal of acquired immune deficiency syndromes (1999) : 2016.
Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD: A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathogens & immunity 1 (1): 154-164,2016.